Announcements Trials
Browse Landscape

Status

Completed 2Terminated 1

Sponsor Class

OTHER 15INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hereditary Cancer 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Diagnostic Tests, Routine × Clear all
NCT05645133 2023-06-15

QPlus Pediatric Reference Interval

HemoSonics LLC

Terminated
93 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03067389 2019-01-15

Combined Breast Cancer Risk Study

Myriad Genetic Laboratories, Inc.

Completed
553 enrolled

Hereditary Cancer

NCT03081455 2017-08-08

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Myriad Genetic Laboratories, Inc.

Completed
145 enrolled

Hereditary Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡